Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27472697 | 0.98 | LTA4H (0.42) | LTA4HNPC1JAK2RAB9APAX8 | |
| SCHEMBL11638360 | 0.91 | NPC1 (0.45) | LTA4HNPC1JAK2RAB9APAX8 | |
| SCHEMBL11598815 | 0.88 | LTA4H (0.40) | LTA4HNPC1JAK2RAB9APAX8 | |
| SCHEMBL11639542 | 0.88 | NPC1 (0.45) | LTA4HNPC1JAK2RAB9APAX8 | |
| SCHEMBL11583718 | 0.87 | LTA4H (0.43) | LTA4HNPC1JAK2RAB9APAX8 | |
| SCHEMBL27661446 | 0.87 | NPC1 (0.42) | LTA4HNPC1JAK2RAB9APAX8 | |
| SCHEMBL27588621 | 0.87 | NPC1 (0.39) | LTA4HNPC1JAK2RAB9APAX8 | |
| SCHEMBL28170173 | 0.87 | NPC1 (0.42) | LTA4HNPC1JAK2RAB9APAX8 | |
| SCHEMBL27772826 | 0.85 | NPC1 (0.38) | LTA4HNPC1JAK2RAB9APAX8 | |
| SCHEMBL27627935 | 0.85 | TLR8 (0.40) | LTA4HNPC1JAK2RAB9APAX8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-52083811-A | — | — | None | — | — | JP | disclosed |
| US-7723065-B2 | Conditions for reactions mediated by yeast | VICTORIA UNIVERSITY (AU) | 2010-05-25 | — | — | US | disclosed |
| WO-2008026227-A2 | A PROCESS FOR THE PREPARATION OF ATOMOXETINE HYDROCHLORIDE | MATRIX LABORATORIES LTD (IN) | 2008-03-06 | — | — | WO | disclosed |
| US-7268166-B2 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | NPS PHARMACEUTICALS, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-7087765-B2 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | NPS PHARMACEUTICALS, INC. (US) | 2006-08-08 | — | — | US | disclosed |
| US-20060142594-A1 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | MUELLER ALAN L | 2006-06-29 | — | — | US | disclosed |
| US-20050084943-A1 | New conditions for reactions mediated by yeast | VICTORIA UNIVERSITY OF TECHNOLOGY (AU) | 2005-04-21 | — | — | US | disclosed |
| CN-1153568-C | Compounds active at a novel side on receptor-operated calcium channel useful for treatment of neurological disorders | NPSҩ������˾ | 2004-06-16 | — | — | CN | disclosed |
| US-6750244-B2 | NERVOUS SYSTEM DISORDERS | NPS PHARMACEUTICALS, INC. | 2004-06-15 | — | — | US | disclosed |
| EP-0831799-B1 | COMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNELS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS | NPS PHARMA INC (US) | 2003-05-02 | — | — | EP | disclosed |
| US-20020004522-A1 | Nervous system disorders | NPS PHARMACEUTICALS, INC. | 2002-01-10 | — | — | US | disclosed |
| US-6211245-B1 | DRUGS FOR CONTROLLING CALCIUM MODULATORS | NPS PHARMACEUTICALS, INC. | 2001-04-03 | — | — | US | disclosed |
| CN-1192679-A | Compounds active at a novel side on receptor-operated calcium channel useful for treatment of neurological disorders | N P S PHARMACEUTICALS INC (US) | 1998-09-09 | — | — | CN | disclosed |
| EP-0831799-A1 | COMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNELS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS | NPS PHARMACEUTICALS, INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996040097-A1 | COMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNELS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS | NPS PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| JP-S5283811-A | ARYLOXY PHENYL PROPYLAMINES AND THEIR SALTS | LILLY CO ELI | 1977-07-13 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142594-A1 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | NCS1, ATP2A1, CACNA1D | LTA4H 1296/4885NPC1 1409/4885JAK2 4352/4885 |
| US-20020004522-A1 | Nervous system disorders | HIF1A, PYGB, LDHB | LTA4H 2627/4885NPC1 328/4885JAK2 3532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.